Published in Curr Pharm Des on January 01, 2010
GABAergic contributions to alcohol responsivity during adolescence: insights from preclinical and clinical studies. Pharmacol Ther (2014) 0.92
Alcohol use disorders in the elderly: a brief overview from epidemiology to treatment options. Exp Gerontol (2012) 0.85
Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. Acta Pharmacol Sin (2014) 0.84
Long-term γ-hydroxybutyric acid (GHB) and disulfiram combination therapy in GHB treatment-resistant chronic alcoholics. Int J Environ Res Public Health (2011) 0.77
Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease. Biomolecules (2016) 0.77
Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study. Am J Crit Care (2013) 0.75
A case of gait disturbance caused by low-dose gabapentin. Ther Clin Risk Manag (2016) 0.75
Reinforcing effectiveness of midazolam, ethanol, and sucrose: behavioral economic comparison of a mixture relative to its component solutions. Behav Pharmacol (2017) 0.75
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int (2014) 2.23
Liver transplantation for patients with alcoholic liver disease: an open question. Dig Liver Dis (2011) 2.14
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol (2002) 2.01
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol (2012) 2.00
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol (2002) 1.85
Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol (2004) 1.83
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol (2010) 1.70
The hepatic apelin system: a new therapeutic target for liver disease. Hepatology (2008) 1.67
Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol (2004) 1.67
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int (2012) 1.56
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. J Clin Gastroenterol (2010) 1.45
Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut (2010) 1.44
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut (2010) 1.29
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol (2010) 1.22
Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis (2009) 1.18
Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology (2013) 1.17
Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer (2010) 1.15
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol (2007) 1.14
The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol (2011) 1.11
A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol (2009) 1.10
Posttransplantation lymphoproliferative disorders. Arch Intern Med (2003) 1.09
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol (2006) 1.08
Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol (2006) 1.08
The reduced tolerance of rat fatty liver to ischemia reperfusion is associated with mitochondrial oxidative injury. J Surg Res (2005) 1.05
Interactions of the heart and the liver. Eur Heart J (2013) 1.04
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. Stem Cells (2006) 1.01
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut (2011) 1.00
Alcohol use in adults. N Engl J Med (2013) 0.99
Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med (2002) 0.98
The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab (2009) 0.97
Stem cells for end stage liver disease: how far have we got? World J Gastroenterol (2008) 0.96
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner? Liver Transpl (2010) 0.93
QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol (2003) 0.92
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol (2007) 0.92
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis. Lab Invest (2011) 0.92
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol (2007) 0.90
Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med (2013) 0.90
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol (2005) 0.89
Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology (2014) 0.88
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One (2013) 0.88
Role of contrast-enhanced ultrasonography in primary hepatic lymphoma. J Ultrasound Med (2010) 0.88
Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int (2012) 0.88
Sudden unexpected fatal encephalopathy in adults with OTC gene mutations-Clues for early diagnosis and timely treatment. Orphanet J Rare Dis (2014) 0.87
Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int (2005) 0.87
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol (2008) 0.86
C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med (2009) 0.86
Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int (2010) 0.86
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol (2011) 0.86
Liver transplantation from donors aged 80 years and over: pushing the limit. Am J Transplant (2004) 0.86
Alcohol use disorders in the elderly: a brief overview from epidemiology to treatment options. Exp Gerontol (2012) 0.85
Variable activation of phosphoinositide 3-kinase influences the response of liver grafts to ischemic preconditioning. J Hepatol (2009) 0.85
Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol (2012) 0.84
Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol (2011) 0.84
Alcohol misuse and traffic accidents. Lancet (2007) 0.84
Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. Gastroenterology (2009) 0.84
Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol (2013) 0.84
Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol (2007) 0.82
Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation. Eur J Gastroenterol Hepatol (2003) 0.82
Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis (2010) 0.82
A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. J Hepatol (2005) 0.81
Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health (2009) 0.81
Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma. J Hepatol (2002) 0.81
Indirect comparison between subcutaneous biologic agents in ankylosing spondylitis. Clin Drug Investig (2015) 0.81
QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol (2007) 0.81
Successful treatment of CCl4-induced acute liver failure with portal vein arterialization in the rat. J Surg Res (2006) 0.80
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. Liver Int (2014) 0.80
Acquired intestinal lymphangiectasia successfully treated with a low-fat and medium-chain triacylglycerol-enriched diet in a patient with liver transplantation. Eur J Gastroenterol Hepatol (2006) 0.80
Combined mechanical and pharmacologic thrombolysis for portal vein thrombosis in liver-graft recipients and in candidates for liver transplantation. Transplantation (2004) 0.80
Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity. Eur Neuropsychopharmacol (2011) 0.79
Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma. Liver Int (2007) 0.79
Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. Clin Neuropharmacol (2005) 0.79
Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis (2012) 0.79
An innovative hyperbaric hypothermic machine perfusion protects the liver from experimental preservation injury. ScientificWorldJournal (2012) 0.79
Portal hypertension and liver cirrhosis in rats: effect of the β3-adrenoceptor agonist SR58611A. Br J Pharmacol (2012) 0.79
Sodium oxybate in maintaining alcohol abstinence in alcoholic patients according to Lesch typologies: a pilot study. J Psychopharmacol (2013) 0.79
Relationship between hepatic haemodynamics assessed by Doppler ultrasound and liver stiffness. Dig Liver Dis (2011) 0.78
Use of alcohol during the treatment of alcohol dependence with gamma-hydroxybutyric acid: risk of severe events are avoided by the dose fractioning of the drug. J Clin Psychopharmacol (2007) 0.78
Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin. Liver Int (2007) 0.78
Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation (2002) 0.78
Hepatic artery stenosis in liver transplanted patients treated with pegylated interferon alpha-2b and ribavirin. Transplantation (2004) 0.78
Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant (2009) 0.78
Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. J Hepatol (2008) 0.78
Liver and partial atrium transplantation for chronic Budd-Chiari syndrome. Liver Transpl (2007) 0.78
Disturbances of acid-base balance in cirrhosis: a neglected issue warranting further insights. Liver Int (2005) 0.77
Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report. BMJ Case Rep (2009) 0.77
The nutritional status modulates preservation-reperfusion injury in rat fatty liver. J Surg Res (2005) 0.76
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. J Gastroenterol (2007) 0.76
Vitamins in the treatment of chronic viral hepatitis. Br J Nutr (2011) 0.76
Renal sodium retention in preascitic cirrhosis: expanding knowledge, enduring uncertainties. Hepatology (2002) 0.76
Treatment of alcohol-use disorders. Lancet (2009) 0.76
Gamma-hydroxybutyrate as a treatment for alcoholism. Lancet (2005) 0.75
Efficacy and safety of γ-hydroxybutyrate in treating alcohol withdrawal syndrome in an alcohol-dependent inpatient with decompensated liver cirrhosis: a case report. J Clin Psychopharmacol (2011) 0.75
Effect of liver transplantation on tuftsin activity and phagocytic activity of neutrophil granulocytes in patients with liver cirrhosis. Int Arch Allergy Immunol (2005) 0.75
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. World J Gastroenterol (2009) 0.75
Sodium oxybate to treat alcohol dependence: 20 years of clinical experience. Addict Biol (2013) 0.75